DSGN
NASDAQ · Biotechnology
Design Therapeutics Inc
$12.18
-0.44 (-3.49%)
Open$12.62
Previous Close$12.62
Day High$13.36
Day Low$12.06
52W High$17.25
52W Low$3.95
Volume—
Avg Volume453.4K
Market Cap875.52M
P/E Ratio—
EPS$-1.19
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+384.0% upside
Current
$12.18
$12.18
Target
$58.95
$58.95
$40.84
$58.95 avg
$77.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 133.74M | 128.39M | 127.15M |
| Net Income | -5,858,142 | -5,637,576 | -5,243,986 |
| Profit Margin | -4.4% | -4.4% | -4.1% |
| EBITDA | -5,607,781 | -6,075,682 | -5,861,844 |
| Free Cash Flow | -4,251,021 | -4,814,286 | -3,496,781 |
| Rev Growth | +7.4% | +3.0% | +5.7% |
| Debt/Equity | 0.91 | 1.04 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |